Coherent Corp.
COHRCoherent Corp. is coiled. The quarters are improving, yet the P/E sits at the 28th percentile of its own 5-year range — the business is moving before the market.
Biggest watch item: the price is already 65 weeks into its uptrend — timing risk, not thesis risk.
The price is in a confirmed uptrend (65 weeks in) while the P/E sits at the 28th percentile of its own 5-year range. Underneath, the last four quarters read improving — profit +700.0% year on year, and 107% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Coherent Corp. trades at $290, in a confirmed uptrend and 65 weeks into that stage. That is +3.0% against its own 200-day average. It sits at 65% of a 52-week range of $107 to $390. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (6 weeks and counting).
Today the stock is in a confirmed uptrend — week 65 of stage 2. At $290 it trades +3.0% versus its 200-day average and sits at 65% of its 52-week range ($107–$390).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved +1,427% while the S&P 500 moved +255% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (6 weeks and counting; last ahead the week of 2026-08-07) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Coherent Corp. trades at 70.4× P/E, near the bottom of its own range — cheaper only 28% of the time. Its long-run median P/E is 93.5×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 70.4× is near the bottom of its own range — cheaper only 28% of the time, against a long-run median of 93.5× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Coherent Corp. reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +22.5% | +11.3% | +18.0% | — |
| Profit | +2,533.3% | — | +21.4% | — |
| EPS | — | — | +11.7% | — |
| Stock price | +165.7% | +107.6% | +36.8% | +29.1% |
4-Factor Sector Score
57.4/100 — rank 4 of 19 in Scientific & Technical Instruments · 71% evidence confidence
Coherent Corp. scores 57.4 out of 100 against the 19 companies it is compared with in Scientific & Technical Instruments, ranking 4. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 28.5 + 6.9 + 8.7 + 13.3 = 57.4. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Coherent Corp. reported $2.0 B of revenue in the Jun 26 quarter, +34.0% year on year. That is the 9th straight quarter of year-on-year growth. Over 5 years it has compounded at 18.0% a year. The last full year, FY26, came in at $7.1 B. The last four reported quarters add to $7.1 B.
FY26 revenue came in at $7.1 B (+22.5% on the year), capping 5 years at 18.0% compound. The latest quarter (Jun 26) printed $2.0 B, +34.0% year on year — the 9th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +22.5% growth against the decade's 18.0% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +22.7% over the last 4 quarters against +23.2%/yr over the last 8 — stabilising.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Coherent Corp.'s operating margin is 12.2% in the Jun 26 quarter, +11.5 percentage points against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged −0.8% to 12.9%. The current quarter sits inside that band.
The latest quarter's operating margin is 12.2%, +11.5 pp against the same quarter a year ago. Across 6 fiscal years the operating margin has ranged −0.8%–12.9%.
Why the margin moved: operating margin went +11.5 pp year on year while gross margin went +2.6 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Coherent Corp. earned $0.2 B of net profit in the Jun 26 quarter, +700.0% year on year. Full-year FY26 profit was $0.8 B. The 5-year compound rate is 21.4%. That is 11.7% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 4 of the last 12 reported quarters were loss-making.
Jun 26 profit was $0.2 B, +700.0% year on year. On the full year, FY26 printed $0.8 B (+2,533.3%), and the 5-year compound rate is 21.4%.
Why profit moved: revenue contributed +34.0% and the margin +11.5 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +596.7% vs revenue +22.5%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 107% of Coherent Corp.'s reported profit arrived as operating cash — the cash follows the profit. In FY26 that was $0.1 B of operating cash against $0.8 B of profit. After $1.1 B of capital spending, $−1.0 B was left as free cash.
FY26: operating cash of $0.1 B against reported profit of $0.8 B, leaving free cash of $−1.0 B after $1.1 B of capital spending. Across the last 3 fiscal years the conversion rate is 107% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Coherent Corp. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $2.0 B over the last 3 years. Averaged over those years that is 9.4% of FY26 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $2.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Coherent Corp. earns a ROE of 7% in FY26. That is up from a trough of −5% in FY23. Return on invested capital clears the cost of that capital by −8.5 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 11.1% net margin on 0.39× asset turns.
FY26 ROE is 7%, recovered from a FY23 trough of −5% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 11.1% net margin × 0.39× asset turns × 1.63× balance-sheet leverage ≈ 7.1% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 6.7% − 15.2% = a −8.5 pp spread. The 15.2% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Dividend
Coherent Corp. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.
Coherent Corp. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Coherent Corp. carries total debt of $3.5 B against shareholder equity of $11.2 B as of Jun 26, a debt-to-equity of 0.31. On the annual view that ratio went from 0.42 in FY21 to 0.31 in FY26. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $3.5 B against shareholder equity of $11.2 B — a debt-to-equity of 0.31. On the annual view, debt-to-equity went from 0.42 (FY21) to 0.31 (FY26). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
3.4% of Coherent Corp.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 1.5 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 3.4% of the float is sold short, and at typical trading volumes it would take about 1.5 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Coherent Corp.: the Z-score reads 4.10. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 4.10 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 4.10.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Garmin Ltd.GRMN | 71.5/100Favorable setup81% evidence | BREAKING OUT | 23.3/35 Revenue 13.5% · PAT 19.7% · OPM change 4.4 pp 83% evidence | 17.0/25 ROCE 6.9% · OPM 30.4% 76% evidence | 13.4/20 P/E 24× · PEG 1.22 65% evidence | 17.8/20 RS sector 9.9% · RS bench 8.9% · 1Y 17.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.3 + 17 + 13.4 + 17.8 = 71.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Keysight Technologies, Inc.KEYS | 68.7/100Favorable setup81% evidence | ASLEEP | 28.2/35 Revenue 19.2% · PAT 44.6% · OPM change 7.9 pp 83% evidence | 15.0/25 ROCE 4.5% · OPM 23.7% 76% evidence | 11.0/20 P/E 57.6× · PEG 1.35 65% evidence | 14.5/20 RS sector 14.3% · RS bench 12.2% · 1Y 80.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 28.2 + 15 + 11 + 14.5 = 68.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Cognex CorporationCGNX | 60.3/100Thin evidence · provisional56% evidence | ASLEEP | 22.1/35 Revenue — · PAT — · OPM change 4.9 pp 39% evidence | 14.9/25 ROCE 3.4% · OPM 22.3% 76% evidence | 9.4/20 P/E 58.5× · PEG — 15% evidence | 13.9/20 RS sector 10.1% · RS bench 8.3% · 1Y 29.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 22.1 + 14.9 + 9.4 + 13.9 = 60.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Coherent Corp.this pageCOHR | 57.4/100Mixed-positive evidence71% evidence | ASLEEP | 28.5/35 Revenue 22.5% · PAT 100% · OPM change 12 pp 83% evidence | 6.9/25 ROCE 1.8% · OPM 12.4% 76% evidence | 8.7/20 P/E 95.7× · PEG — 15% evidence | 13.3/20 RS sector 11.3% · RS bench 8.7% · 1Y 165.7%2 of 12 weeks ahead 100% evidence |
| Exact sum: 28.5 + 6.9 + 8.7 + 13.3 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Ituran Location and Control Ltd.ITRN | 53.1/100Thin evidence · provisional60% evidence | ASLEEP | 15.9/35 Revenue 11.3% · PAT 6.9% · OPM change -0.1 pp 53% evidence | 15.9/25 ROCE 8.6% · OPM 21.5% 57% evidence | 10.3/20 P/E 16.2× · PEG 1.8 65% evidence | 11.0/20 RS sector -0.5% · RS bench -1.9% · 1Y 44.5%0 of 12 weeks ahead 70% evidence |
| Exact sum: 15.9 + 15.9 + 10.3 + 11 = 53.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Mesa Laboratories, Inc.MLAB | 51.6/100Thin evidence · provisional51% evidence | BREAKING OUT | 16.1/35 Revenue 3.7% · PAT — · OPM change 1.9 pp 40% evidence | 6.3/25 ROCE 0.9% · OPM 4.3% 57% evidence | 9.2/20 P/E 73.1× · PEG — 15% evidence | 20.0/20 RS sector 29.3% · RS bench 27.8% · 1Y 71.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 6.3 + 9.2 + 20 = 51.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Sensata Technologies Holding plcST | 49.7/100Thin evidence · provisional56% evidence | ASLEEP | 18.2/35 Revenue — · PAT — · OPM change 1.7 pp 39% evidence | 11.0/25 ROCE 2.7% · OPM 15.1% 76% evidence | 9.0/20 P/E 79.6× · PEG — 15% evidence | 11.5/20 RS sector 2.8% · RS bench 1.5% · 1Y 34%5 of 12 weeks ahead 100% evidence |
| Exact sum: 18.2 + 11 + 9 + 11.5 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Vontier CorporationVNT | 49.1/100Thin evidence · provisional56% evidence | FADING | 16.1/35 Revenue — · PAT — · OPM change 0.4 pp 39% evidence | 14.7/25 ROCE 3.6% · OPM 18% 76% evidence | 11.3/20 P/E 12.5× · PEG — 15% evidence | 7.0/20 RS sector -16.8% · RS bench -16.9% · 1Y -27.1%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 14.7 + 11.3 + 7 = 49.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9MKS Inc.MKSI | 48.2/100Mixed-negative evidence66% evidence | ASLEEP | 20.1/35 Revenue 11.5% · PAT 43.4% · OPM change 1.9 pp 53% evidence | 10.2/25 ROCE 2.1% · OPM 13.8% 57% evidence | 13.6/20 P/E 48.1× · PEG 1.13 65% evidence | 4.3/20 RS sector -6% · RS bench -8% · 1Y 82.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 10.2 + 13.6 + 4.3 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Trimble Inc.TRMB | 47.7/100Thin evidence · provisional56% evidence | BREAKING OUT | 20.1/35 Revenue — · PAT — · OPM change 3.7 pp 39% evidence | 10.5/25 ROCE 1.9% · OPM 15.3% 76% evidence | 10.4/20 P/E 33.1× · PEG — 15% evidence | 6.7/20 RS sector -20.4% · RS bench -20.2% · 1Y -30.8%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 10.5 + 10.4 + 6.7 = 47.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Novanta Inc.NOVT | 47.2/100Thin evidence · provisional56% evidence | ASLEEP | 21.4/35 Revenue — · PAT — · OPM change 4.5 pp 39% evidence | 9.8/25 ROCE 2% · OPM 10.7% 76% evidence | 8.9/20 P/E 84.8× · PEG — 15% evidence | 7.1/20 RS sector -5.3% · RS bench -6.4% · 1Y 15.8%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 9.8 + 8.9 + 7.1 = 47.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Teledyne Technologies IncorporatedTDY | 45.7/100Mixed-negative evidence81% evidence | ASLEEP | 15.2/35 Revenue 7.9% · PAT 13.5% · OPM change 1.6 pp 83% evidence | 13.1/25 ROCE 2.5% · OPM 20% 76% evidence | 8.2/20 P/E 30.1× · PEG 2.15 65% evidence | 9.2/20 RS sector -5.5% · RS bench -6.4% · 1Y 6.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 13.1 + 8.2 + 9.2 = 45.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Badger Meter, Inc.BMI | 44.7/100Thin evidence · provisional56% evidence | ASLEEP | 13.7/35 Revenue — · PAT — · OPM change -4.8 pp 39% evidence | 15.4/25 ROCE 4.8% · OPM 17.4% 76% evidence | 10.1/20 P/E 34.7× · PEG — 15% evidence | 5.5/20 RS sector -22% · RS bench -21.8% · 1Y -28%5 of 12 weeks ahead 100% evidence |
| Exact sum: 13.7 + 15.4 + 10.1 + 5.5 = 44.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Itron, Inc.ITRI | 43.6/100Thin evidence · provisional56% evidence | BREAKING OUT | 14.6/35 Revenue — · PAT — · OPM change -1.1 pp 39% evidence | 9.6/25 ROCE 2.5% · OPM 11.5% 76% evidence | 11.1/20 P/E 14.4× · PEG — 15% evidence | 8.3/20 RS sector -10.5% · RS bench -10.6% · 1Y -23.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 9.6 + 11.1 + 8.3 = 43.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15Fortive CorporationFTV | 40.7/100Thin evidence · provisional53% evidence | ASLEEP | 15.8/35 Revenue — · PAT — · OPM change -5.6 pp 32% evidence | 8.2/25 ROCE 1.7% · OPM 9% 76% evidence | 10.3/20 P/E 33.3× · PEG — 15% evidence | 6.4/20 RS sector -7.7% · RS bench -8.5% · 1Y 13.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 8.2 + 10.3 + 6.4 = 40.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 16ESCO Technologies Inc.ESE | 40.1/100Mixed-negative evidence66% evidence | ASLEEP | 18.0/35 Revenue 30.7% · PAT 16.7% · OPM change -0.5 pp 53% evidence | 13.1/25 ROCE 2.8% · OPM 15.5% 57% evidence | 4.7/20 P/E 54.2× · PEG 6 65% evidence | 4.3/20 RS sector -6.9% · RS bench -8.2% · 1Y 21.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 13.1 + 4.7 + 4.3 = 40.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Vishay Precision Group, Inc.VPG | 31.6/100Thin evidence · provisional56% evidence | ASLEEP | 13.3/35 Revenue — · PAT — · OPM change -3.2 pp 39% evidence | 4.5/25 ROCE 0.1% · OPM 0.4% 76% evidence | 8.5/20 P/E 99.5× · PEG — 15% evidence | 5.3/20 RS sector -4.6% · RS bench -7.2% · 1Y 85.4%5 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 4.5 + 8.5 + 5.3 = 31.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18USBC, Inc.USBC | 43.6/100Thin evidence · provisional20% evidence | BREAKING OUT | 17.3/35 Revenue — · PAT — · OPM change — 2% evidence | 11.1/25 ROCE — · OPM — 11% evidence | 11.5/20 P/E 0.9× · PEG — 15% evidence | 3.7/20 RS sector -22.6% · RS bench -21.4% · 1Y -50.5%4 of 12 weeks ahead 70% evidence |
| Exact sum: 17.3 + 11.1 + 11.5 + 3.7 = 43.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19MicroVision, Inc.MVIS | 30.4/100Thin evidence · provisional39% evidence | 10.6/35 Revenue -80% · PAT — · OPM change -129 pp 40% evidence | 6.8/25 ROCE -35.2% · OPM — 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -68.3% · RS bench -66.3% · 1Y -76.9%0 of 4 weeks ahead to 2026-07-24 70% evidence | |
| Exact sum: 10.6 + 6.8 + 10 + 3 = 30.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Coherent Corp.'s stock price today?
Coherent Corp. trades at $290, +165.7% over the past year. The company is valued at $57.0 B. The stock sits at 65% of its 52-week range of $107–$390, +3.0% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 65 weeks in. — as of 17 September 2026.
What were Coherent Corp.'s latest quarterly results?
Coherent Corp. reported revenue of $2.0 B and net profit of $0.2 B for the Jun 26 quarter. Revenue rose 34.0% and profit rose 700.0% year on year. Earnings per share were $1.19. The operating margin was 12.2%, 11.5 pp higher than a year earlier. — as of 17 September 2026.
What is Coherent Corp.'s revenue?
Coherent Corp. reported revenue of $2.0 B in the Jun 26 quarter, +34.0% year on year. For the full FY26 fiscal year, revenue was $7.1 B (+22.5%). Over the last 5 years revenue compounded at 18.0% a year. — as of 17 September 2026.
What is Coherent Corp.'s profit?
Coherent Corp. earned $0.2 B of net profit in the Jun 26 quarter, +700.0% year on year. Full-year FY26 profit was $0.8 B. The operating margin ran 12.2% in the latest quarter. — as of 17 September 2026.
What is Coherent Corp.'s market cap?
Coherent Corp.'s market capitalisation is $57.0 B at a stock price of $290. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Coherent Corp.'s P/E ratio?
Coherent Corp. trades at a P/E of 70.4×, at the 28th percentile of its own 5-year range, against a long-run median of 93.5×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Coherent Corp. pay a dividend?
No — Coherent Corp. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.
Is Coherent Corp. overvalued?
On its own history, Coherent Corp. looks cheap: its P/E of 70.4× has been cheaper only 28% of the time in 5 years (long-run median 93.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is Coherent Corp. growing?
Yes — Coherent Corp. is growing: latest-quarter revenue +34.0% year on year, profit +700.0%, and the margin +11.5 pp at 12.2%. The 5-year compound rates are 18.0% (revenue) and 21.4% (profit). The earnings engine currently reads: improving — as of 17 September 2026.
How is Coherent Corp. performing?
Coherent Corp. is in a confirmed uptrend, 65 weeks in. Its latest quarter's revenue rose 34.0% and profit rose 700.0% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
Is Coherent Corp. in an uptrend?
Yes — the price is in a confirmed uptrend (week 65 of stage 2), trading +3.0% versus its 200-day average and at 65% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Coherent Corp. beating the market?
Not lately — on a trailing-13-week view Coherent Corp. is currently behind the S&P 500 (6 weeks and counting; last ahead the week of 2026-08-07), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved +1,427% against the S&P 500's +255% — ahead of the index over the full window. — as of 17 September 2026.
Will Coherent Corp.'s stock price go up?
This page publishes no price forecast for Coherent Corp. What it measures instead: the stock price is $290, the price is in a confirmed uptrend 65 weeks in. Its P/E of 70.4× sits at the 28th percentile of its own 5-year range. — as of 17 September 2026.
Is the market betting against Coherent Corp.?
Somewhat — short interest is 3.4% of Coherent Corp.'s tradable float, about 1.5 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Coherent Corp. have too much debt?
It is moderate — Coherent Corp.'s debt-to-equity is 0.32. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Coherent Corp.'s capex?
Coherent Corp. spent $2.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was $1.1 B. — as of 17 September 2026.
What is Coherent Corp.'s cash flow?
Coherent Corp. generated $0.1 B of operating cash flow in FY26 and $−1.0 B of free cash flow after $1.1 B of capital spending. Reported profit that year was $0.8 B, so operating cash ran behind profit. — as of 17 September 2026.
Is Coherent Corp.'s profit real cash?
Yes — over the last 3 fiscal years, 107% of Coherent Corp.'s reported profit arrived as operating cash. Though the latest year ran at 10% — the trend is the thing to watch. In FY26, operating cash was $0.1 B against reported profit of $0.8 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Coherent Corp.?
On the balance sheet, the Z-score reads 4.10 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Coherent Corp. in its business cycle?
Coherent Corp.'s FY26 operating margin was 12.6%, against a 6-year band of −0.8%–12.9%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 12.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Coherent Corp. story?
Biggest watch item: the price is already 65 weeks into its uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Coherent Corp. a stock worth studying right now?
This is not investment advice. The machine read: Coherent Corp. is coiled. The quarters are improving, yet the P/E sits at the 28th percentile of its own 5-year range — the business is moving before the market. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!